Kynexis Therapeutics
PrivateLast Round
Series A
Aug 19, 2026
Total Funding Raised
$220M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Kynexis Therapeutics operates in Healthcare & Life Sciences and is based in Naarden. Its latest recorded funding round was a Series A round in August 2026.
Kynexis Therapeutics is a biotechnology company developing precision therapeutics for brain diseases, with a focus on cognitive impairment associated with schizophrenia (CIAS).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kynexis Therapeutics Comparables
Compare Kynexis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurosterix | 83% | |
| Phrenix Therapeutics | 80% | |
| Alto Neuroscience | 79% |
For institutional investors. Book with your work email.
Kynexis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 19, 2026 | ||||
| Series A | Nov 7, 2023 |
For institutional investors. Book with your work email.
Kynexis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series A |
| Ysios Capital | Series A |
| Sunstone Life Science Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 19, 2026
$110M round led by nvfund
- Jul 24, 2026
Monthly visitors grew 181% MoM, reaching 2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 21, 2026
Kynexis appoints John McDonald, former Head of M&A at Novo and current Operating Partner of Business Development and M&A at Forbion, as an advisor.
- receives_financingAug 19, 2026
Kynexis raises $46.3M in a Series A financing extension on Aug 21st '26, led by Novartis Venture Fund with Forbion, Ysios Capital and Sunstone Life Science Ventures participating, to advance its Phase 2 study of KYN-5356 and prepare for potential registrational trials.
- receives_financingAug 19, 2026
Kynexis receives $46.3M Series A1 financing through a Series A extension led by Novartis Venture Fund, with participation from Forbion, Ysios Capital, and Sunstone Life Science Ventures, to advance KYN-5356 for cognitive impairment associated with schizophrenia in Netherlands on Aug 19th '26.
- hiresAug 19, 2026
As part of its financing, Kynexis appoints Mathias Frederiksen as a Board Observer on Aug 24th '26.
- hiresAug 19, 2026
Novartis Venture Fund's Marianne Uteng joins Kynexis's Board of Directors in connection with its financing on Aug 24th '26.
For institutional investors. Book with your work email.
Kynexis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kynexis Therapeutics's valuation, stock price, and market status.
Is Kynexis Therapeutics a public or private company?
Kynexis Therapeutics is a private company.
What is the current stock price of Kynexis Therapeutics?
Kynexis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Kynexis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kynexis Therapeutics worth (valuation)?
Valuation information for Kynexis Therapeutics is not publicly available.
Can I buy Kynexis Therapeutics stock?
Kynexis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kynexis Therapeutics's last funding round?
Kynexis Therapeutics's most recent funding round was Series A on August 19, 2026.
Who are the main investors in Kynexis Therapeutics?
Key investors in Kynexis Therapeutics include Forbion.
Will Kynexis Therapeutics IPO soon?
No public IPO plans have been announced for Kynexis Therapeutics.
How can I track Kynexis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Kynexis Therapeutics's shares on secondary markets.